New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 29, 2012
13:51 EDTARNA, VVUS, OREXVIVUS drug's CV profile viewed positively by FDA, says Rodman & Renshaw
After attending an FDA panel hearing focused on the effects of anti-obesity drugs on cardiovascular systems, Rodman & Renshaw believes that the FDA and the panel are comfortable with the cardiovascular profile of VIVUS' drug, Qnexa. The firm indicates that it doesn't expect the agency to require additional cardiovascular tests before Qnexa is approved, and it reiterates an Outperform rating on VIVUS.
News For VVUS;ARNA;OREX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
08:21 EDTOREXOrexigen Contrave sales encouraging, says RBC Capital
Subscribe for More Information
07:22 EDTOREXOrexigen Contrave off to strong start, says JMP Securities
Subscribe for More Information
February 25, 2015
06:33 EDTOREXOrexigen reports Q4 EPS 0c, consensus 21c
Subscribe for More Information
February 24, 2015
16:01 EDTVVUSVIVUS reports Q4 EPS (25c), consensus (25c)
Reports Q4 revenue $21.7M, consensus $20.01M.
09:03 EDTOREXUltragenyx adds Orexigen CEO to board
Ultragenyx Pharmaceutical (RARE) announced the appointment of Michael Narachi to the company's board, effective February 20. Narachi, President and CEO and a director of Orexigen Therapeutics (OREX), will serve as an independent director to Ultragenyx.
08:10 EDTOREXOrexigen resumed with an Outperform at Leerink
Target $8.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use